Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
P/E ratio for Benitec Biopharma Inc. (BNTC)
P/E ratio as of 2024: -1.36
According to Benitec Biopharma Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.36. At the end of 2023 the company had a P/E ratio of -0.29.
P/E ratio history for Benitec Biopharma Inc. from 2013 to 2024
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2024 | -1.36 |
| 2023 | -0.29 |
| 2022 | -0.51 |
| 2021 | -1.32 |
| 2020 | -0.97 |
| 2019 | 4.82 |
| 2018 | -3.31 |
| 2017 | -4.82 |
| 2016 | -0.65 |
| 2015 | -9.11 |
| 2014 | -9.73 |
| 2013 | -4.42 |